Cart
sales@molnova.com
Methyl 4-bromopyrrole-2-carboxylate
CAS No. 934-05-4
Methyl 4-bromopyrrole-2-carboxylate( methyl 4-bromo-1H-pyrrole-2-carboxylate | 4-Bromo-2-(methoxycarbonyl)-1H-pyrrole )
Catalog No. M29527 CAS No. 934-05-4
Methyl 4-bromopyrrole-2-carboxylate is a marine derived natural products found in Lissodendoryx sp.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | 27 | In Stock |
|
Biological Information
-
Product NameMethyl 4-bromopyrrole-2-carboxylate
-
NoteResearch use only, not for human use.
-
Brief DescriptionMethyl 4-bromopyrrole-2-carboxylate is a marine derived natural products found in Lissodendoryx sp.
-
DescriptionMethyl 4-bromopyrrole-2-carboxylate is a marine derived natural products found in Lissodendoryx sp.
-
In Vitro——
-
In Vivo——
-
Synonymsmethyl 4-bromo-1H-pyrrole-2-carboxylate | 4-Bromo-2-(methoxycarbonyl)-1H-pyrrole
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number934-05-4
-
Formula Weight204.02
-
Molecular FormulaC6H6BrNO2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : ≥ 100 mg/mL (490.15 mM)
-
SMILESO=C(OC)C1=CC(Br)=CN1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Rezatomidine
Rezatomidine (AGN-203818) is an effective and selective alpha2-adrenergic receptor antagonist for the treatment of chronic pain, including neuropathic pain.
-
Dexrazoxane
A derivative of EDTA that chelates iron and reduces the number of metal ions complexed with anthracycline and, consequently, decrease the formation of superoxide radicals.
-
5-HT3 antagonist 5
5-HT3 antagonist 5 is a quinoxalin-2-carboxamide compound that acts as a 5-HT3 receptor antagonist, counteracting 5-HT3 agonist and 2-methyl-5-HT, and demonstrating an anti-depressant effect in mice .
